Dec 19, 2019
ESMO IO 2019 Phase 1 Results for Indoximod Plus Radiation and Chemotherapy in DIPG
Dec 18, 2019
SABCS 2019 Phase 2 Results for Indoximod Plus Taxane Chemotherapy in Metastatic Breast Cancer
May 23, 2019
I-O 2019 <b>World Congress Phase 1 results for NLG802</b>
Apr 2, 2019
AACR 2019 <b>Phase 2 Results for NLG207 Plus Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer</b>
Dec 2, 2018
ASH 2018 <strong>Updated Phase 1 Data of Indoximod Plus Standard Induction Chemotherapy in Newly Diagnosed AML </strong>
Nov 9, 2018
SITC 2018 <strong>Phase 1 Pharmacokinetic Data for NLG802 Prodrug</strong>
Nov 9, 2018
SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Advanced Melanoma</strong>
Nov 9, 2018
SITC 2018 <strong>Indoximod Impact on Tumor Microenvironment from Phase 2 Study of Patients with Metastatic Pancreatic Cancer</strong>
Jul 1, 2018
ISPNO 2018 <strong>Updated Phase 1 Data for Indoximod Plus Radio-Immunotherapy for Pediatric Patients with Newly Diagnosed DIPG</strong>
Jun 4, 2018
ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Pembrolizumab in Advanced Melanoma</strong>
Jun 3, 2018
ASCO 2018 <strong>Phase 2 Results for Indoximod Plus Gemcitabine/nab-Paclitaxel in Metastatic Pancreatic Cancer</strong>
Apr 17, 2018
AACR 2018 <strong>Indoximod Modulates AhR-driven Transcription of Genes That Control Immune Function</strong>
Apr 15, 2018
AACR 2018 <strong>Phase 1 Study of Indoximod Plus Radiation & Chemotherapy for Pediatric Patients with DIPG and Other Brain Tumors</strong>
Nov 20, 2017
SNO 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>
Nov 10, 2017
TCH 2017 <strong>Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer</strong>
Sep 2, 2017
CIC 2017 <strong>Interim Phase 2 of Indoximod plus Pembrolizumab in Advanced Melanoma</strong>
Jun 22, 2017
EHA 2017 <strong>Phase I Indoximod plus Idarubicin & Cytarabine for Newly Diagnosed Acute Myeloid Leukemia</strong>
Jun 5, 2017
ASCO 2017 <strong>Phase II Double-blind study of Metastatic Castration-resistant Prostate Cancer</strong>
Apr 4, 2017
AACR Plenary 2017 <strong>Indoximod plus Keytruda (pembrolizumab) Phase II Interim in Advanced Melanoma</strong>
Apr 4, 2017
AACR 2017 <strong>NLG802 Prodrug Poster Presentation</strong>
Nov 22, 2016
SNO 2016 <strong>Indoximod + Temozolomide Brain Tumor Trial</strong>
Jun 5, 2016
ASCO 2016 <strong>Pancreas indoximod</strong>
Jun 5, 2016
ASCO 2016 <strong>Melanoma indoximod</strong>
Apr 20, 2016
ASCO GI 2016 <strong>Indoleamine Phase II Trial</strong>
Jan 22, 2016
ASCO GI <strong>Indoximod + Gemcitabine/nab-Paclitaxel</strong>
Dec 15, 2015
SABCS 2015 <strong>Indoximod Phase II Metastatic Breast Cancer Trial</strong>
Nov 6, 2015
SITC 2015 <strong>GDC-0919 + PD-L1</strong>
Oct 20, 2015
ECCO-ESMO 2015 <strong>Indoximod + Ipilimumab Melanoma Trial</strong>
Sep 29, 2015
ESMO 2015 <strong>GDC-0919</strong>
Jun 1, 2015
ASCO 2015 <strong>Indoximod and Temozolomide</strong>
Jul 28, 2014
IUMS <strong>Highly efficacious influenza vaccination using HyperAcute® Technology</strong>
Jun 2, 2014
ASCO 2014 <strong>Algenpantucel-L</strong>
Jun 2, 2014
ASCO 2014 <strong>Sipuleucel-T +- Indoximod</strong>
Jun 1, 2014
ASCO 2014 <strong>Tergenpumatucel-L vs. Docetaxel</strong>
Jun 1, 2014
ASCO 2014 <strong>Docetaxel + Indoximod</strong>
